{"id":"zoladex-and-casodex","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"10–50","effect":"Gynecomastia"},{"rate":"40–70","effect":"Erectile dysfunction"},{"rate":"20–40","effect":"Fatigue"},{"rate":"5–15","effect":"Injection site reaction (Zoladex)"},{"rate":"10–20","effect":"Diarrhea (Casodex)"},{"rate":"1–3","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zoladex (goserelin) is a GnRH agonist that initially stimulates then suppresses luteinizing hormone and follicle-stimulating hormone, leading to castrate levels of testosterone. Casodex (bicalutamide) is a non-steroidal androgen receptor antagonist that blocks residual androgens and receptor signaling. Together, they provide maximal androgen deprivation therapy (MAD) by eliminating both androgen production and receptor activation.","oneSentence":"Zoladex suppresses testosterone production via GnRH agonism, while Casodex blocks androgen receptors, together providing dual hormonal blockade for androgen-dependent cancers.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:45.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic prostate cancer"},{"name":"Locally advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids (Zoladex only)"}]},"trialDetails":[{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT02454543","phase":"NA","title":"Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martini-Klinik am UKE GmbH","startDate":"2015-05","conditions":"Prostate Cancer","enrollment":452},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT05513365","phase":"PHASE2","title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-09-27","conditions":"Salivary Duct Carcinoma","enrollment":26},{"nctId":"NCT00328614","phase":"PHASE1","title":"Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2003-03","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT00544830","phase":"PHASE2","title":"Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-18","conditions":"PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":29},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":146},{"nctId":"NCT00223145","phase":"PHASE3","title":"Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abdenour Nabid","startDate":"2000-12","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT00099086","phase":"PHASE1","title":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-01-16","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00482807","phase":"PHASE1","title":"Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-08-31","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT00541047","phase":"PHASE3","title":"RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2007-11","conditions":"Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction","enrollment":4236},{"nctId":"NCT00651326","phase":"PHASE3","title":"Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-06-02","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT00771017","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-07","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05140512","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-02-04","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT02058706","phase":"PHASE2","title":"LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2014-05","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":71},{"nctId":"NCT00055731","phase":"PHASE3","title":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-11-14","conditions":"Prostate Cancer","enrollment":413},{"nctId":"NCT00004124","phase":"PHASE3","title":"S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1999-10-15","conditions":"Prostate Cancer","enrollment":983},{"nctId":"NCT03971110","phase":"PHASE4","title":"A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"Advanced Prostate Cancer","enrollment":9},{"nctId":"NCT02064036","phase":"PHASE1","title":"Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06-06","conditions":"Adenocarcinoma of the Prostate","enrollment":17},{"nctId":"NCT00005044","phase":"PHASE3","title":"Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-02","conditions":"Prostate Cancer","enrollment":1579},{"nctId":"NCT04563936","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-01-06","conditions":"Prostate Cancer","enrollment":290},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT00003653","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1999-01-05","conditions":"Prostate Cancer","enrollment":1386},{"nctId":"NCT04622761","phase":"PHASE2","title":"Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome","status":"NOT_YET_RECRUITING","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2021-01-15","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT00303784","phase":"PHASE3","title":"Prostate Adenocarcinoma TransCutaneous Hormones","status":"UNKNOWN","sponsor":"University College, London","startDate":"2006-03","conditions":"Anemia, Cardiovascular Complications, Hot Flashes","enrollment":2200},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT02059213","phase":"PHASE2","title":"A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT02742675","phase":"PHASE2","title":"Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT00003645","phase":"PHASE3","title":"Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-06-14","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT00002633","phase":"PHASE3","title":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1995-02-08","conditions":"Prostate Cancer","enrollment":361},{"nctId":"NCT04220398","phase":"NA","title":"Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-01-10","conditions":"Prostate Cancer, Chemotherapy Effect, Hormone Sensitive Prostate Cancer","enrollment":475},{"nctId":"NCT03587285","phase":"PHASE1, PHASE2","title":"A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2018-09-23","conditions":"Prostatic Neoplasms","enrollment":11},{"nctId":"NCT00669162","phase":"PHASE1, PHASE2","title":"Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2012-08","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT00850941","phase":"","title":"Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-01-26","conditions":"Prostate Cancer","enrollment":146},{"nctId":"NCT00528866","phase":"PHASE2","title":"Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT00298155","phase":"PHASE2","title":"Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-07","conditions":"Cancer, Prostate Neoplasms","enrollment":35},{"nctId":"NCT00283803","phase":"PHASE2","title":"Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2002-03-12","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT00165399","phase":"PHASE2","title":"Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2004-03","conditions":"Adenocarcinoma of the Prostate, Prostate Cancer","enrollment":62},{"nctId":"NCT01120236","phase":"PHASE2","title":"Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer","enrollment":211},{"nctId":"NCT00589472","phase":"PHASE2","title":"Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":19},{"nctId":"NCT02911350","phase":"PHASE1","title":"Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2000-05","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT00658697","phase":"PHASE2","title":"Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-06","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT00170157","phase":"PHASE2","title":"Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-06","conditions":"Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":112},{"nctId":"NCT00002651","phase":"PHASE3","title":"SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-05","conditions":"Prostate Cancer","enrollment":3040},{"nctId":"NCT00769795","phase":"PHASE2","title":"Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-10","conditions":"Prostate Cancer","enrollment":29},{"nctId":"NCT00776594","phase":"PHASE2","title":"Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-10","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT01120262","phase":"","title":"S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2010-02","conditions":"Prostate Cancer","enrollment":545},{"nctId":"NCT00021450","phase":"PHASE3","title":"Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-04","conditions":"Prostate Cancer","enrollment":819},{"nctId":"NCT02678520","phase":"PHASE2","title":"Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients","status":"WITHDRAWN","sponsor":"University of Kansas Medical Center","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00006359","phase":"PHASE2","title":"Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-09","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT00586898","phase":"PHASE2","title":"Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-07","conditions":"Prostate, Cancer, Hormonal Cycling","enrollment":36},{"nctId":"NCT00067015","phase":"PHASE3","title":"Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-05","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT00108732","phase":"PHASE2","title":"A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-02","conditions":"Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":50},{"nctId":"NCT00631527","phase":"PHASE1","title":"Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT00666666","phase":"PHASE2","title":"R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":"Adenocarcinoma of the Prostate, Stage IV Prostate Cancer","enrollment":55},{"nctId":"NCT01531205","phase":"PHASE2","title":"Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":2},{"nctId":"NCT00349557","phase":"PHASE2","title":"Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Benaroya Research Institute","startDate":"2006-04","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT01250717","phase":"PHASE2","title":"Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-01","conditions":"Prostate Cancer","enrollment":28},{"nctId":"NCT00884273","phase":"PHASE3","title":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-08","conditions":"Prostate Cancer","enrollment":182},{"nctId":"NCT00831233","phase":"PHASE3","title":"Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-04","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT00348998","phase":"PHASE2","title":"Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"UNKNOWN","sponsor":"Virginia Mason Hospital/Medical Center","startDate":"2006-04","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT00026377","phase":"PHASE1","title":"SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-11","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT00028769","phase":"PHASE2","title":"S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-12","conditions":"Prostate Cancer","enrollment":41},{"nctId":"NCT00012090","phase":"PHASE2","title":"Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-09","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00512668","phase":"PHASE1","title":"Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":24},{"nctId":"NCT00833248","phase":"PHASE3","title":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-04","conditions":"Prostate Cancer","enrollment":246},{"nctId":"NCT00014586","phase":"PHASE3","title":"Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-01","conditions":"Prostate Cancer","enrollment":110},{"nctId":"NCT00388804","phase":"PHASE3","title":"External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-02","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT00841113","phase":"PHASE3","title":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Speciality European Pharma Limited","startDate":"1999-01","conditions":"Prostate Cancer","enrollment":177},{"nctId":"NCT00536653","phase":"NA","title":"Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Wirral University Teaching Hospital NHS Trust","startDate":"1999-10","conditions":"Osteoporosis","enrollment":618},{"nctId":"NCT00255268","phase":"PHASE4","title":"CMAB vs IMAB in Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Metastatic Prostate Cancer","enrollment":15},{"nctId":"NCT00293696","phase":"PHASE4","title":"Casodex/Zoladex Biomarkers in Localised Prostate Cancer","status":"COMPLETED","sponsor":"Tampere University","startDate":"2004-10","conditions":"Prostate Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Zoladex and Casodex","genericName":"Zoladex and Casodex","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoladex suppresses testosterone production via GnRH agonism, while Casodex blocks androgen receptors, together providing dual hormonal blockade for androgen-dependent cancers. Used for Metastatic prostate cancer, Locally advanced prostate cancer, Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}